Description

Raxibacumab is a fully human monoclonal antibody specifically developed for the treatment and prophylaxis of inhalational anthrax. This product is a critical therapeutic agent that targets the protective antigen component of *Bacillus anthracis* toxin, neutralizing its lethal effects. It is essential for biodefense stockpiles, hospital emergency preparedness, and research into bacterial toxin neutralization mechanisms. Raxibacumab CAS NO 565451-13-0 represents a high-purity, pharmaceutical-grade solution for global public health and security applications.

Application

• Therapeutic Treatment for Inhalational Anthrax: Used in combination with appropriate antibacterial drugs for the treatment of inhalational anthrax.
• Post-Exposure Prophylaxis (PEP): Administered for the prophylaxis of inhalational anthrax following suspected or confirmed exposure to *Bacillus anthracis* spores.
• Strategic National Stockpile (SNS): A key component of government and military biodefense stockpiles for emergency response scenarios.
• Hospital and Public Health Preparedness: Integrated into emergency medical protocols and inventory for rapid deployment in the event of a bioterrorism incident.
• Research and Development: Serves as a reference standard and active ingredient in preclinical and clinical studies focused on anthrax and monoclonal antibody therapeutics.
• Biosimilar Development: Used as a comparator in the development and analytical characterization of biosimilar monoclonal antibody candidates.

Basic Information

Product Name	Raxibacumab
CAS No.	565451-13-0
Molecular Formula	C6442H9916N1720O2016S46
Molecular Weight	Approx. 145 kDa
Synonyms	ABthrax; Human Anti-Bacillus Anthracis Protective Antigen Monoclonal Antibody; Anti-PA Human IgG1λ; Monoclonal Antibody to *Bacillus anthracis* Protective Antigen; Raxibacumab (USAN/INN); Recombinant Human IgG1 Anti-Protective Antigen Monoclonal Antibody; CAS 565451-13-0; UNII-8G8LZ7L6VU
EINECS	Contact for details

Quality Control

Our Raxibacumab is manufactured under strict cGMP conditions, ensuring the highest standards of purity, potency, and consistency. Each batch is subjected to a comprehensive battery of analytical tests, including identity confirmation by peptide mapping and mass spectrometry, purity assessment by size exclusion and ion exchange chromatography, and rigorous testing for host cell proteins, DNA, and endotoxins. Certificates of Analysis (COA) detailing full specifications and test results are provided and comply with relevant pharmacopeial and regulatory guidelines (e.g., FDA, EMA).

Storage

Preserve in the original, tightly closed container as supplied. Store refrigerated at 2°C to 8°C. Do not freeze. Protect from light. This product is hygroscopic (moisture-sensitive); ensure containers are kept sealed to maintain stability and prevent moisture ingress. Keep out of reach of children.

Specification

Item	Specification
Appearance	Clear to slightly opalescent, colorless to pale yellow solution
Identification (Peptide Map)	Conforms to Reference Standard
Purity (SEC-HPLC)	≥ 98.0% Monomer
Purity (CEX-HPLC)	Main peak conforms to reference
Protein Content (A280)	As per COA
Potency (Cell-Based Assay)	Meets release criteria
pH	6.0 - 7.0
Endotoxins (LAL)	< 1.0 EU/mg
Host Cell Proteins (ELISA)	< 100 ppm
Host Cell DNA (qPCR)	< 10 pg/mg
Sterility (Membrane Filtration)	Sterile

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.